Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level

doi:10.1158/1055-9965.EPI-10-0674

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2012 February 1.

Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2011 February; 20(2): 234–238.

Published online 2011 January 6. doi: 10.1158/1055-9965.EPI-10-0674

PMCID: PMC3077576

NIHMSID: NIHMS260488

Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level

Andrew A. Strasser,¹ Neal L. Benowitz,² Angela G. Pinto,¹ Kathy Z. Tang,¹ Stephen S. Hecht,³ Steve G. Carmella,³ Rachel F. Tyndale,⁴ and Caryn E. Lerman¹

¹Department of Psychiatry and Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania

²Division of Clinical Pharmacology and Experimental Therapeutics, University of California San Francisco, San Francisco, California

³Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota

⁴Centre for Addiction and Mental Health, and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario

CORRESPONDING AUTHOR: Andrew A. Strasser, Department of Psychiatry and Abramson Cancer Center, University of Pennsylvania, 3535 Market Street; Suite 4100; Philadelphia, PA 19104-3309 USA; phone (215) 746-5788; fax (215) 746-7140 ; Email: strasse3/at/mail.med.upenn.edu

The publisher's final edited version of this article is available free at Cancer Epidemiol Biomarkers Prev

See other articles in PMC that cite the published article.

Abstract

Background

Variability in smoking behavior is partly attributable to heritable individual differences in nicotine clearance rates. This can be assessed as the ratio of the metabolites cotinine (COT) and 3'-hydroxycotinine (3HC) (referred to as the nicotine metabolism ratio, NMR). We hypothesized that faster NMR would be associated with greater cigarette puff volume and higher levels of total NNAL, a carcinogen biomarker.

Methods

Current smokers (n=109) smoked one of their preferred brand cigarettes through a smoking topography device and provided specimens for NMR and total NNAL assays.

Results

Faster nicotine metabolizers (third and fourth quartiles versus first quartile) based on the NMR exhibited significantly greater total puff volume and total NNAL; the total puff volume by daily cigarette consumption interaction was a significant predictor of total NNAL level.

Conclusion

A heritable biomarker of nicotine clearance predicts total cigarette puff volume and total NNAL.

Impact

If validated, the NMR could contribute to smoking risk assessment in epidemiological studies and potentially in clinical practice.

The substantial variability in smoking behavior is attributable, in part, to heritable individual differences in nicotine clearance rates (1). Nicotine, the primary addictive compound in tobacco, is metabolized to cotinine (COT), and then to 3'-hydroxycotinine (3HC), predominantly by the hepatic CYP2A6 enzyme (2, 3). Smokers can extract varying levels of nicotine by altering their smoking topography (e.g., puff volume, number of puffs) (4–6), which in turn can affect level of toxin exposure (6–8).

To provide a non-invasive assessment of CYP2A6 activity, a phenotypic marker has been characterized (9). The ratio of 3HC/COT, referred to as the nicotine metabolite ratio (NMR), reflects CYP2A6 genetic variation as well as environmental factors influencing CYP2A6 activity and therefore nicotine clearance in vivo (10). The NMR is highly reproducible and independent of time since last cigarette (9, 11). Faster metabolizers of nicotine have higher smoking rates (12), and therefore may have increased risk for lung cancer (13, 14). We hypothesized that smokers with higher NMRs (faster nicotine metabolism) will exhibit: (1) increased total puff volume, reflecting efforts to extract more nicotine from their cigarettes, and (2) increased total NNAL levels, reflecting the effect of total puff volume on toxin exposure. If confirmed, the NMR would be of value in assessment of risk from cigarette smoking.

Materials and Methods

To test this hypothesis, 109 smokers of ≥10 cigarettes per day and ages 18–65 years were recruited from participants in a nicotine replacement therapy trial (for exclusion criteria see 15). The study protocol was approved by the Institutional Review Board of the University of Pennsylvania and all other analytical sites.

Participants were recruited from April 2005 to February 2006. Following informed consent and prior to initiating treatment, they completed measures of demographics, smoking history, current cigarette brand, and nicotine dependence level (Fagerstrom Test of Nicotine Dependence; FTND;16). They provided a 15ml blood sample for analysis of nicotine metabolites, assayed at the University of California, San Francisco via liquid chromatography with tandem mass spectrometry (9). Genotyping for CYP2A6 variants was performed at the Centre for Addiction and Mental Health (Toronto, Canada) as previously described (17). A 30ml urine sample was provided and assayed for total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), the sum of NNAL and its glucuronides, at the University of Minnesota per standard procedures (18).

In a smoking-approved ventilated room, participants smoked one of their own brand cigarettes under ad libitum conditions, using a smoking topography device (Clinical Research Support System; Borgwaldt, Richmond VA) validated in prior research (19, 20). Participants were asked to refrain from smoking for one hour prior to their laboratory smoking session, and were generally compliant (mean 64.3 minutes; SD=35.4, range 42–190). Total puff volume, defined as the sum of all puffs taken, was a priori selected as the outcome measure for analysis (21, 22).

NMR values were positively skewed (+1.8) and have positive kurtosis (+4.8) consistent with previously results, and was therefore log-transformed (15, 17). NMR quartiles were created (15, 23) and CYP2A6 genotypes were coded as described previously (17). NMR quartiles, previously determined from Received Operator Characteristic analyses, have been used to characterize smokers' response to transdermal nicotine treatment and bupropion (15; 17; 24), and therefore were used in this study to assist comparisons to previous research that utilized NMR. Hypotheses were tested using analysis of covariance (ANCOVA) where total puff volume and total NNAL were the outcome measures and NMR quartile was the between group factor. Fisher's post-hoc analyses were used to identify quartile differences. Regression analysis was used to examine the association between log-transformed NMR and total puff volume, as well as with NNAL. Stepwise regression analysis was used to examine the association between smoking behavior (daily cigarette consumption, total puff volume, and their product as an index of daily puff volume) and total NNAL levels, retaining covariates at p<.2.

Results

The participant sample was 59% male, 96% Caucasian with an average age of 45.4 (SD=10.8) years old. On average, they had been smoking for 29.3 years (SD=11.2), smoked an average of 20.5 cigarettes per day (SD=8.4), with an average nicotine dependence score of 4.9 (SD=2.1). Most participants smoked a Light brand (55%) and non-menthol (71%) cigarette. This study sample is similar to the full clinical study sample, [n=568; (see 15)], but with a significantly greater proportion of Caucasians (84% in the full sample). Of the 142 who attended these initial intake sessions, 131 (92%) agreed to complete a smoking topography assessment with their own brand cigarettes; 14 withdrew prior to having assays completed, 5 had contaminated urine samples, and 3 had failed topography assessment. Topography session completers did not differ from non-completers on demographic or smoking variables.

Mean plasma NMR value was 0.395 (SD=0.20; range 0.012–1.246). Mean, standard deviation, lower and upper limits for quartiles were: 1) 0.192 (SD=0.06; 0.010–0.259); 2) 0.313 (SD=0.03; 0.260–0.357); 3) 0.410 (SD=.036; 0.358–0.477); 4) 0.668 (SD=0.21; 0.478–1.246) (additional data see Table 1). Females were more likely to be in the highest NMR (faster metabolism; p=.02), consistent with prior reports that women metabolize nicotine faster than men (25). NMR was non-significantly higher among participants who were older (p=.10), had higher nicotine dependence levels (p=.09), and who smoked non-menthol cigarettes (p=.10). Thus, these variables were included as covariates.

Table 1

Mean (Standard Deviation), unless noted otherwise. Note: Reg.=Regular cigarette; Lt.=Light cigarette; U-Lt=Ultra-Light cigarette, based on Federal Trade Commission (FTC) cigarette classifications used at the time data was collected (FTC, 2000).

Mean total puff volume was 785.1 ml (SD=284.9; range 247.4–1776.1). There was an overall association of NMR quartiles with total puff volume (F=2.62, p=.05); smokers in the third quartile (p=.042) and fourth quartile (p=.016) exhibited significantly higher total puff volumes than those in the first quartile (Table 1; Figure 1a). Faster metabolizers by CYP2A6 (*1/*1, n=89) genotype also had higher puff volumes than slower metabolizers (defined as any of *2, *4, *9, *12 variants, n=19); means were 816.8 ml (SD=292.0) vs. 643.3 ml (SD=206.9), respectively (F=6.04, p=.02) (results the same when the 5 non-European ancestry subjects were excluded).

Figure 1

Association of the NMR with total puff volume and NNAL. (A) NMR quartiles versus total puff volume (ml). Results are mean values +/− standard error (F=2.62, p=.05). Post-hoc comparisons indicate a significant difference between first and third (more ...)

Mean total NNAL was 1.47 pmol/mg creatinine (SD=0.79; range 0.10–4.2). There was a significant main effect of the NMR (F=3.59, p=.02); smokers in the third quartile (p=.001) and fourth quartile (p=.033) had higher total NNAL levels than those in the first quartile (Table 1; Figure 1b). A similar, non-significant difference was seen in genotypic fast versus slow metabolizers (1.54 pmol/mg creatinine [SD=.92] vs. 1.34 pmol/mg creatinine [SD=.68]), p=.35). Results were unchanged when the nicotine dependence (FTND) covariate was replaced with smoking rate.

Linear regression analysis indicated a positive association between log-transformed NMR and total puff volume (beta=321.2, t=2.35, p=.024, R² =.051); and log-transformed NMR and total NNAL (beta=.831, t=2.41, p=.02, R² =.052). Stepwise regression analysis indicated that the total puff volume by daily cigarette consumption product was positively associated with total NNAL level (beta=2.538×10⁻⁵, t=2.94, p=.004), controlling for sex (p=.02), years smoking (p=.04), and menthol (p=.16); the overall model was significant [F(4,104)=4.85, p=.001, R²=.16).

Discussion

This study is the first to show that a heritable biomarker of nicotine clearance, the NMR, predicts total cigarette puff volume and overall carcinogen exposure based on total NNAL. Compared to the slowest metabolizers (first quartile), smokers in the third and fourth quartiles exhibited 23% and 28% increases in cigarette puff volume respectively, and total NNAL levels that are 61% and 53% higher, respectively. These results are consistent with our prior study (26) and current results showing increased puff volume among fast metabolizers by CYP2A6 genotype. Results potentially could be interpreted as faster metabolizers take greater puffs to obtain a desired, greater level of nicotine, or that slow metabolizers smoke less intensely to avoid excessive or toxic nicotine levels. We suggest that it is more likely that faster metabolizers smoke more to obtain a desired level of nicotine, as there is little support for slow metabolizers reporting nausea when learning to smoke (27) and in high dose transdermal nicotine studies, continued smoking did not lead to signs of nicotine toxicity (28).

The availability of a phenotypic measure of CYP2A6 activity, such as the NMR, is useful as it captures both genetic, such as yet unidentified alleles or other genes, and environmental influences, such as estrogen levels (25), on CYP2A6 activity and nicotine clearance and NMR can be measured noninvasively (e.g., saliva) without additional drug administration (29, 30).

Cigarette smoking causes the majority of lung cancer cases (31) and total NNAL is a biomarker for one of the most prevalent systemic lung carcinogens in tobacco (32,33). Yet, there is substantial variability in lung cancer risk at a given level of smoking (34, 35). This may be attributable to individual differences in the amount of toxin exposure per cigarette, as well as in activation in carcinogens (13). Because lung cancer can take years to develop, the identification of practical biomarkers to improve risk assessment would be of great value.

There are some limitations of this study. Although puff volume is reliable and stable (19, 20), repeated assessments, rather than the single assessment here, may better reflect daily smoking patterns. Participants in this study were restricted to treatment-seeking smokers who smoked >10 cigarettes per day, and may not represent the general smoking population. One might postulate that since slow metabolizers have lower daily cigarette consumption, a high percentage may have not met study inclusion criteria (26). Therefore, these findings should also be replicated in a population-based sample. Lastly, a more comprehensive biomarker panel that includes not only the NMR, but also information on cigarette brand features (e.g., filter ventilation; 6), and diurnal variations in smoking patterns (36) may provide a more refined assessment of risk from smoking. Such measures could potentially enhance risk assessment in epidemiological studies and, if replicated, could be translated in the future to clinical practice.

Acknowledgments

Funding This research was supported by grants from the National Cancer Institute and the National Institutes on Drug Abuse at the National Institutes of Health: P50 CA/DA84718, CA143187 (CL), U01 DA020830 (NB, RT, CL), R01 CA120594 (AS) and R01 CA130961 (AS); and Canadian Institutes of Health Research: MOP86471 (RFT).

References

1. Ray R, Tyndale RF, Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. Journal of Neurogenetics. 2009;23(3):252–261. [PubMed]

2. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics. 1997;282(3):1608–1614. [PubMed]

3. Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H, et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clinical Pharmacology and Therapeutics. 2001;69(1):72–78. [PubMed]

4. Strasser AA, Tang KZ, Sanborn PM, Zhou JY, Kozlowski LT. Behavioral filter vent blocking on the first cigarette of the day predicts which smokers of light cigarettes will increase smoke exposure from blocked vents. Experimental and Clinical Psychopharmacology. 2009;17(6):405–12. [PubMed]

5. Benowitz NL, Jacob P, 3rd, Herrera B. Nicotine intake and dose response when smoking reduced-nicotine content cigarettes. Clinical Pharmacology Therapeutics. 2006;80(6):703–714. [PubMed]

6. Djordjevic MV, Stellman SD, Zang E. Doses of nicotine and lung carcinogens delivered to cigarette smokers. Journal of the National Cancer Institute. 2000;92(2):106–111. [PubMed]

7. Strasser AA, Pickworth WB, Patterson F, Lerman C. Smoking topography predicts abstinence following treatment with nicotine replacement therapy. Cancer Epidemiology, Biomarkers and Prevention. 2004;13(11):1800–1804. [PubMed]

8. Strasser AA, O'Connor RJ, Mooney ME, Wileyto EP. Digital image analysis of cigarette filter stains as an indicator of compensatory smoking. Cancer Epidemiology Biomarkers and Prevention. 2006;15(12):2565–2569. [PubMed]

9. Dempsey D, Tutka P, Jacob P, 3rd, Allen F, Schoedel K, Tyndale RF. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clinical Pharmacology and Therapeutics. 2004;76:64–72. [PubMed]

10. Benowitz NL, Hukkanen J, Jacob P., 3rd Nicotine chemistry, metabolism, kinetics and biomarkers. Handbook Experimental Pharmacology. 2009;(192):29–60. [PMC free article] [PubMed]

11. Lea RA, Dickson S, Benowitz NL. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. Journal Analytical Toxicology. 2006;30(6):386–389. [PubMed]

12. Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P., III Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine and Tobacco Research. 2003;5:621–624. [PubMed]

13. Tyndale RF, Sellers EM. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metabolism and Disposition. 2001;29:548–552. [PubMed]

14. London S, Idle J, Daly A, Coetzee G. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet. 1999;353:898–899. [PubMed]

15. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: A validation study. Pharmacology, Biochemistry and Behavior. 2009;92:6–11. [PMC free article] [PubMed]

16. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction. 1991;86(9):1119–1127. [PubMed]

17. Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, Benowitz N, Tyndale RF. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clinical Pharmacology and Therapeutics. 2010 doi: 10.1038/clpt.2010.3. [PubMed]

18. Carmella SG, Han S, Fristad A, Yang Y, Hecht SS. Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Cancer Epidemiology Biomarkers Prevention. 2003;12:1257–1261. [PubMed]

19. Strasser AA, Ashare RL, Kozlowski LT, Pickworth WB. The effect of filter vent blocking and smoking topography on carbon monoxide levels in smokers. Pharmacology, Biochemistry and Behavior. 2005;82(2):320–329. [PubMed]

20. Lee E, Malson JL, Waters AJ, Moolchan ET, Pickworth WB. Smoking topography: reliability and validity in dependent smokers. Nicotine and Tobacco Research. 2003;5:673–679. [PubMed]

21. Strasser AA, Lerman C, Sanborn PM, Pickworth W, Feldman E. New lower nicotine cigarettes produce compensatory smoking and increased carbon monoxide exposure. Drug and Alcohol Dependence. 2007;86(2–3):294–300. [PubMed]

22. Benowitz NL, Jacob P, 3rd, Bernert JT, Wilson M, Wang L, Allen F, Dempsey D. Carcinogen exposure during short-term switching from regular to “light” cigarettes. Cancer Epidemiology Biomarkers Prevention. 2005;14(6):1376–1383. [PubMed]

23. Lerman C, Tyndale RF, Patterson F, Wileyto EP, Shields PG, Pinto A, Benowitz NL. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clinical Pharmacology and Therapeutics. 2006;79:600–608. [PubMed]

24. Patterson F, Schnoll RA, Wileyto EP, et al. Toward personalized therapy for smoking cessation: A randomized placebo-controlled trial of bupropion. Clinical Pharmacology and Therapeutics. 2008;84(3):320–325. [PubMed]

25. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P., 3rd Female sex and oral contraceptive use accelerate nicotine metabolism. Clinical Pharmacology Therapeutics. 2006;79(5):480–488. [PubMed]

26. Strasser AA, Malaiyandi V, Hoffmann E, Tyndale R, Lerman C. An association of CYP2A6 genotype and smoking topography. Nicotine and Tobacco Research. 2007;9(4):511–518. [PubMed]

27. Audrain-McGovern J, Al Koudsi N, Rodriguez D, Wileyto EP, Shields PG, Tyndale RF. The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics. 2007;119(1):264–274. [PubMed]

28. Benowitz NL, Zevin S, Jacob P., 3rd Suppression of nicotine intake during ad libitum cigarette smoking by high dose transdermal nicotine. The Journal of Pharmacology and Experimental Therapeutics. 1998;287(3):958–962. [PubMed]

29. Swan GE, Benowitz NL, Lessov CN, Jacob P, III, Tyndale RF, Wilhelmsen K. Nicotine metabolism: The impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenetic Genomics. 2005;15:115–125. [PubMed]

30. Benowitz NL, Dains KM, Dempsey D, Herrera B, Yu L, Jacob P., 3rd Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. Nicotine Tobacco Research. 2009;11(8):954–960. [PMC free article] [PubMed]

31. International Agency for Research on Canerer. (IARC) IARC monographs on the evaluation of carcinogenic risks to humans. IARC; Lyon, France: 2004. Tobacco smoke and involuntary smoking.

32. Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncology. 2002;3:46–469. [PubMed]

33. Hecht SS. Tobacco smoke carcinogens and lung cancer. Journal of the National Cancer Institute. 1999;91:1194–1210. [PubMed]

34. United States Department of Health and Human Services The Health Consequences of Smoking: A Report of the Surgeon General. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; Atlanta, GA: 2004.

35. Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. Journal of the American Medical Association. 2005;294:1505–1510. [PubMed]

36. Muscat JE, Stellman SD, Caraballo RS, Richie JP., Jr. Time to first cigarette after waking predicts cotinine levels. Cancer Epidemiology Biomarkers Prevention. 2009;18(12):3415–3420. [PMC free article] [PubMed]